文献速递血栓与止血

甲氨蝶呤联合凝血因子IX预防可减轻血友病性关节病

Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy.
PubMed 文献 · J Thromb Haemost · 2026-05-12

在血友病B小鼠模型中,反复膝关节穿刺诱导血友病性关节病后,预防性甲氨蝶呤(MTX)联合延长半衰期凝血因子IX(EHL-FIX)预防治疗可减轻滑膜炎严重程度、降低滑膜血管密度并减少软骨损伤,但延迟MTX治疗仅减少滑膜增生、血管化和巨噬细胞浸润,未改善软骨侵蚀和蛋白聚糖丢失。

要点

  • 预防性MTX联合EHL-FIX可减轻滑膜炎和软骨损伤。
  • 延迟MTX治疗未改善软骨侵蚀和蛋白聚糖丢失。
  • MTX联合FIX预防可能作为疾病修饰辅助治疗。

核心结论

  • MTX联合FIX预防治疗可限制实验性血友病性关节病的软骨损伤和病理性滑膜血管生成。

研究设计与样本

  • 血友病B小鼠接受3次双周膝关节穿刺诱导反复关节出血。
  • 第一部分:EHL-FIX预防治疗(100 IU/kg静脉每3天一次)单用或联合MTX(20 mg/kg皮下每周一次)6周。
  • 第二部分:MTX延迟至3次关节穿刺后开始。
  • 关节结局通过组织学和磁共振成像评估。

主要发现

  • 膝关节直径测量和磁共振成像确认所有损伤小鼠均成功诱导关节出血和滑膜炎。
  • 预防性MTX联合EHL-FIX较单用EHL-FIX减轻滑膜炎严重程度、显著降低滑膜血管密度并减少软骨损伤程度。
  • 延迟MTX联合FIX治疗显著减少滑膜增生、血管化和巨噬细胞浸润,但软骨侵蚀和蛋白聚糖丢失无差异。

临床怎么用

  • MTX联合FIX预防可能作为血友病性关节病的疾病修饰辅助治疗,有待进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In severe hemophilia, recurrent hemarthroses lead to hemophilic arthropathy (HArt), characterized by chronic synovitis and cartilage destruction, reminiscent of rheumatoid arthritis. Unlike inflammatory synovitis, HArt lacks disease-modifying, joint-directed, targeted therapies. OBJECTIVE: To assess whether methotrexate (MTX), a reference treatment for inflammatory synovitis, can reduce joint damage when combined with extended half-life factor IX (EHL-FIX) prophylaxis in a murine model of hemophilia B. METHODS: Hemophilia B mice underwent 3 biweekly knee joint punctures to induce recurrent hemarthroses. In part 1, mice received either EHL-FIX prophylaxis alone (100 IU/kg intravenously every 3 days) or EHL-FIX combined with MTX (20 mg/kg subcutaneously once weekly) for 6 weeks as prophylaxis in an attempt to prevent HArt. In part 2, MTX was delayed until after 3 joint punctures. Joint outcomes were assessed using histology and magnetic resonance imaging scans. RESULTS: Knee diameter measurements and magnetic resonance imaging scans confirmed successful induction of joint bleeding and synovitis in all injured mice in both parts. Prophylactic MTX combined with EHL-FIX reduced the severity of the synovitis, significantly reduced the vascular density in the synovial pannus, and decreased the degree of cartilage damage compared with EHL-FIX alone. Following targeted treatment of chronic synovitis, combined FIX + MTX therapy resulted in significantly reduced synovial hyperplasia, vascularity, and macrophage infiltration. No differences in cartilage erosion and proteoglycan loss were observed. CONCLUSION: MTX combined with FIX prophylaxis limits cartilage damage and pathologic synovial angiogenesis in experimental HArt, supporting its evaluation as a potential disease-modifying adjunct therapy.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Martin C, Valentino LA, Martinez L, et al. Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy. J Thromb Haemost. 2026. PMID: 42119948. doi:10.1016/j.jtha.2026.04.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。